Page 1

chemometec ANNOUNCEMENT NO . 204 6 May 2021 Interim report for Q3 2020/21 ( 1 January - 31 March 2021 ) Revenue and EBITDA growth ChemoMetec continued on its growth trend in Q3 2020/21 and generated revenue of DKK 69.7 million , a 21 % increase on the year - earlier period . The increase was mainly driven by strong growth in the European market and high growth rates within cell - based therapy . EBITDA was DKK 31.6 million in the third quarter , an increase of 12 % , while the EBITDA margin was 45 % . Highlights " ■ " • ■ " ■ Revenue amounted to DKK 69.7 million in Q3 2020/21 , a 21 % increase on the year- earlier period . The strong growth in the European market in the first half year continued in the third quarter , when revenue grew by 77 % . Revenue growth in the North American market was 15 % , which was , however , strongly affected by the weak US dollar . Growth in local currency ( USD ) was 25 % . Revenue in Chemo Metec's core business area , Life Science Research , Cell - based Therapy and Pharmaceutical Process and Quality Control ( LCP ) , increased by 22 % in the third quarter . In the quarter , ChemoMetec sold 60 NC - 202 , the latest cell counter . EBITDA increased to DKK 31.6 million in the third quarter , up from DKK 28.2 million in the year - earlier period , corresponding to an increase of 12 % . The EBITDA margin was 45 % for the quarter . ChemoMetec raised its full - year guidance for 2020/21 on 18 March 2021 , and this guidance is maintained . ChemoMetec A / S Gydevang 43 DK - 3450 Allerod Denmark Phone +45 4813 1020 Fax +45 4813 1021 www.chemometec.com Company reg . ( CVR ) no .